PMID- 33413175
OWN - NLM
STAT- MEDLINE
DCOM- 20210510
LR  - 20240330
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 21
IP  - 1
DP  - 2021 Jan 7
TI  - Cetuximab versus bevacizumab following prior FOLFOXIRI and bevacizumab in 
      postmenopausal women with advanced KRAS and BRAF wild-type colorectal cancer: a 
      retrospective study.
PG  - 30
LID - 10.1186/s12885-020-07770-9 [doi]
LID - 30
AB  - BACKGROUND: An upgraded understanding of factors (sex/estrogen) associated with 
      survival benefit in advanced colorectal carcinoma (CRC) could improve 
      personalised management and provide innovative insights into anti-tumour 
      mechanisms. The aim of this study was to assess the efficacy and safety of 
      cetuximab (CET) versus bevacizumab (BEV) following prior 12 cycles of 
      fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus BEV in 
      postmenopausal women with advanced KRAS and BRAF wild-type (wt) CRC. METHODS: 
      Prospectively maintained databases were reviewed from 2013 to 2017 to assess 
      postmenopausal women with advanced KRAS and BRAF wt CRC who received up to 
      12 cycles of FOLFOXIRI plus BEV inductive treatment, followed by CET or BEV 
      maintenance treatment. The primary endpoints were overall survival (OS), 
      progression-free survival (PFS), response rate. The secondary endpoint was the 
      rate of adverse events (AEs). RESULTS: At a median follow-up of 27.0 months (IQR 
      25.1-29.2), significant difference was detected in median OS (17.7 months [95% 
      confidence interval [CI], 16.2-18.6] for CET vs. 11.7 months [95% CI, 10.4-12.8] 
      for BEV; hazard ratio [HR], 0.63; 95% CI, 0.44-0.89; p=0.007); Median PFS was 
      10.7 months (95% CI, 9.8-11.3) for CET vs. 8.4 months (95% CI, 7.2-9.6) for BEV 
      (HR, 0.67; 95% CI 0.47-0.94; p=0.02). Dose reduction due to intolerable AEs 
      occurred in 29 cases (24 [24.0%] for CET vs. 5 [4.8%] for BEV; p< 0.001). 
      CONCLUSIONS: CET tends to be superior survival benefit when compared with BEV, 
      with tolerated AEs.
FAU - Huang, Chunlong
AU  - Huang C
AD  - Department of Hepatobiliary Surgery, The First Affiliated Hospital, Sun Yat-sen 
      University, No. 58, Zhongshan 2nd Road, Yuexiu District, Guangzhou, 510080, 
      China.
FAU - Gu, Xiaoyuan
AU  - Gu X
AD  - Department of Oncology, Shibei Hospital of Shanghai, No. 4500, Goughexin Road, 
      Jing' an District, Shanghai, 200443, China.
FAU - Zeng, Xianshang
AU  - Zeng X
AD  - Department of Orthopaedics, The First Affiliated Hospital, Sun Yat-sen 
      University, No. 58, Zhongshan 2nd Road, Yuexiu District, Guangzhou, 510080, 
      China.
FAU - Chen, Baomin
AU  - Chen B
AD  - Department of Hepatobiliary Surgery, The First Affiliated Hospital, Sun Yat-sen 
      University, No. 58, Zhongshan 2nd Road, Yuexiu District, Guangzhou, 510080, 
      China.
FAU - Yu, Weiguang
AU  - Yu W
AD  - Department of Orthopaedics, The First Affiliated Hospital, Sun Yat-sen 
      University, No. 58, Zhongshan 2nd Road, Yuexiu District, Guangzhou, 510080, 
      China. 10211270007@fudan.edu.cn.
FAU - Chen, Meiji
AU  - Chen M
AD  - Department of Pediatrics, The First Affiliated Hospital, Sun Yat-sen University, 
      No. 58, Zhongshan 2nd Road, Yuexiu District, Guangzhou, 510080, China. 
      chenmeiji_2016@163.com.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
DEP - 20210107
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (KRAS protein, human)
RN  - 04ZR38536J (Oxaliplatin)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - 7673326042 (Irinotecan)
RN  - EC 2.7.11.1 (BRAF protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
RN  - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
RN  - PQX0D8J21J (Cetuximab)
RN  - Q573I9DVLP (Leucovorin)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Bevacizumab/administration & dosage
MH  - Biomarkers, Tumor/*genetics
MH  - Cetuximab/administration & dosage
MH  - Colorectal Neoplasms/*drug therapy/genetics/pathology
MH  - Female
MH  - Fluorouracil/administration & dosage
MH  - Follow-Up Studies
MH  - Humans
MH  - Irinotecan/administration & dosage
MH  - Leucovorin/administration & dosage
MH  - Middle Aged
MH  - *Mutation
MH  - Neoplasm Metastasis
MH  - Oxaliplatin/administration & dosage
MH  - *Postmenopause
MH  - Prognosis
MH  - Proto-Oncogene Proteins B-raf/*genetics
MH  - Proto-Oncogene Proteins p21(ras)/*genetics
MH  - Retrospective Studies
MH  - Survival Rate
PMC - PMC7789412
OTO - NOTNLM
OT  - Bevacizumab
OT  - Cetuximab
OT  - Colorectal carcinoma
OT  - Overall survival
OT  - Progression-free survival
COIS- The authors declare that they have no competing interests.
EDAT- 2021/01/09 06:00
MHDA- 2021/05/11 06:00
PMCR- 2021/01/07
CRDT- 2021/01/08 05:42
PHST- 2020/08/25 00:00 [received]
PHST- 2020/12/26 00:00 [accepted]
PHST- 2021/01/08 05:42 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/05/11 06:00 [medline]
PHST- 2021/01/07 00:00 [pmc-release]
AID - 10.1186/s12885-020-07770-9 [pii]
AID - 7770 [pii]
AID - 10.1186/s12885-020-07770-9 [doi]
PST - epublish
SO  - BMC Cancer. 2021 Jan 7;21(1):30. doi: 10.1186/s12885-020-07770-9.